Internship

Digital Accelerator Program Internship

Posted on 1/17/2025

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

No H1B Sponsorship

Princeton, NJ, USA

Onsite presence is likely required for this internship.

US Citizenship Required

Category
Applied Machine Learning
AI Research
AI & Machine Learning
Required Skills
UI/UX Design
Requirements
  • Current undergraduate students from an accredited university in Information Technology, Computer Science, Computer Engineering, Computer Information Systems, Management Information Systems, Cybersecurity, Informatics, Information Science/Technology, Software Engineering, Security and Risk Analysis, Bioinformatics, Statistics, Biotechnology, or other relevant STEM majors with IT experience.
  • Candidates must be a US citizen, have a lawful permanent resident of the US or otherwise authorized to work in the US without requiring sponsorship now or in the future.
Responsibilities
  • Technology Development/Configuration
  • Technology Design/Architect
  • Data Engineering
  • Cybersecurity Risk Assessment
  • AI Specialist
  • Application Testing
  • Business Analysis
  • Technology Contact Support
  • Project Management
  • Quality Management
  • UX Design
Desired Qualifications
  • A strong interest in technology with a passion for healthcare
  • Able to collaborate across multiple teams
  • Demonstrated leadership skills inside and/outside academia
  • Excellent written and verbal communication skills
  • Innovative and inquisitive nature to ask questions, offer bold ideas and challenge the status quo
  • Agility to learn new tools and processes

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that meet the same quality and safety standards as their branded counterparts. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, focusing on Environmental, Social, and Governance (ESG) goals. Their goal is to improve patient outcomes by making both innovative and affordable healthcare solutions widely available.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of 2seventy bio enhances BMS's capabilities in cancer cell therapy.
  • Rising demand for biosimilars opens new revenue streams for BMS.
  • Digital health technologies improve R&D efficiency, reducing costs and time to market.

What critics are saying

  • Increased competition in oncology could impact BMS's market share.
  • Patent expirations like Revlimid may lead to revenue loss from generics.
  • FDA scrutiny on drug pricing could pressure BMS's profit margins.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

Reuters
Mar 11th, 2025
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

March 11 (Reuters) - Bristol Myers Squibb (BMY.N) will acquire 2seventy bio (TSVT.O) for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.

INACTIVE